Innovative, Nature-inspired Mechanism, Dissolving Blood Clots Without Inducing Bleeding, Shows Promises of Enhanced Safety and Efficacy ...

LONDON, UK I4, 2024 I Duke Street Bio Ltd, a precision medicine biotech developing next generation small molecule cancer therapies, is pleased to ...

Kisunla™ (donanemab-azbt), pronounced kih-SUHN-lah, is used to treat adults with early symptomatic Alzheimer’s disease (AD), which includes mild cognitive impairment (MCI) or mild dementia stage of ...

TOKYO, Japan I5, 2024 I Kyowa Kirin Co., Ltd. (Kyowa Kirin) (TSE:4151) (President and CEO: Masashi Miyamoto) announced top-line results of the ...

ATLANTA, GA, USA I5, 2024 I UCB, a global biopharmaceutical company, today announced the presentation of new four-year data in patients with ...

Half-life in non-human primates (NHP) of 30.3 days after subcutaneous (SQ) administration and 33.8 days after intravenous (IV) administration ...

Metsera plans to initiate a Phase 2b trial of MET-097 in Q4 2024, with data anticipated in the first half of 2025.

Funding co-led by the Bill & Melinda Gates Foundation and Amplitude Ventures to advance a new class of multi-functional biologics ...

PARIS, France, and HOUSTON, TX, USA I 12, 2024 I As part of its effort to develop innovative treatments for people living with rare cancers, Sanofi ...

LONDON, UK I 09, 2024 I GSK plc (LSE/NYSE: GSK) today presented the full results from the SWIFT-1 and SWIFT-2 phase III clinical trials which ...

Losmapimod failed to show an improvement in relative surface area (RSA), a measure of reachable workspace (RWS), versus placebo at week 48 ― ...

MUNICH & GARCHING, Germany & LAUSANNE, Switzerland I 12, 2024 I ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical ...